Gerrit Weber Selected Research

Neoplasms (Cancer)

1/2024	Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells.
1/2022	Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.
1/2021	GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
1/2019	Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells.
1/2018	Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma.
7/2015	K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo.
5/2015	Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes.
9/2010	Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gerrit Weber Research Topics

Disease

8	Neoplasms (Cancer) 01/2024 - 09/2010
2	Neuroblastoma 01/2024 - 01/2018
2	Glioma (Gliomas) 01/2022 - 01/2021
1	COVID-19 04/2024
1	Brain Neoplasms (Brain Tumor) 01/2022
1	Diffuse Intrinsic Pontine Glioma 01/2022
1	Inflammation (Inflammations) 11/2021
1	Bites and Stings (Sting) 01/2021
1	Hepatocellular Carcinoma (Hepatoma) 01/2021
1	Intellectual Disability (Idiocy) 06/2020
1	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 11/2019
1	Virus Diseases (Viral Diseases) 01/2019
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 09/2013
1	Graft vs Host Disease (Graft-Versus-Host Disease) 12/2011
1	Rhabdomyosarcoma 09/2010
1	Leukemia 01/2007
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2007

Drug/Important Bio-Agent (IBA)

3	Chimeric Antigen ReceptorsIBA 01/2018 - 05/2015
2	GangliosidesIBA 01/2024 - 01/2018
2	CytokinesIBA 11/2021 - 01/2018
1	Adrenergic Agents (Adrenergic Drugs)IBA 01/2024
1	GlycosphingolipidsIBA 01/2024
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 01/2024
1	dipinacoline glutamateIBA 01/2022
1	BMS 754807IBA 01/2022
1	3- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanolIBA 01/2022
1	ChemokinesIBA 11/2021
1	EphA2 ReceptorIBA 01/2021
1	Erythropoietin FDA Link 01/2021
1	Adenylosuccinate lyase deficiencyIBA 06/2020
1	EmapalumabIBA 11/2019
1	Monoclonal AntibodiesIBA 11/2019
1	Interleukin-15 (Interleukin 15)IBA 01/2018
1	Interleukin-7 (Interleukin 7)IBA 01/2018
1	Messenger RNA (mRNA)IBA 05/2015
1	Proteins (Proteins, Gene)FDA Link 05/2015
1	Therapeutic UsesIBA 05/2015
1	heparanaseIBA 05/2015
1	Neoplasm Antigens (Tumor Antigens)IBA 09/2013
1	HLA Antigens (Human Leukocyte Antigens)IBA 12/2011
1	LigandsIBA 09/2010
1	EuropiumIBA 09/2010
1	Carrier Proteins (Binding Protein)IBA 09/2010
1	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 09/2010
1	Histocompatibility Antigens (Histocompatibility Antigen)IBA 09/2010

Therapy/Procedure

4	Therapeutics 01/2024 - 01/2019
3	Stem Cell Transplantation 12/2011 - 01/2007
2	Immunotherapy 01/2024 - 09/2013
1	Assisted Suicide (Physician Assisted Suicide) 04/2024
1	Combined Modality Therapy 01/2021
1	Hematopoietic Stem Cell Transplantation 09/2013